Sandrine Oziel-Taieb1, Marjorie Faure2, Marine Gilabert3, Aurélie Autret4, Olivier Turrini5, Laurence Moureau-Zabotto6, Marc Giovannini7, Frederique Rousseau8, Jean-Luc Raoul9. 1. Department of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. oziels@ipc.unicancer.fr. 2. Department of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. faurem@ipc.unicancer.fr. 3. Department of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. gilabertm@ipc.unicancer.fr. 4. Statistical Unit, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. autreta@ipc.unicancer.fr. 5. Department of Surgical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. turrinio@ipc.unicancer.fr. 6. Department of Radiotherapy, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. moureaul@ipc.unicancer.fr. 7. Department of Interventional Endoscopy, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. giovanninim@ipc.unicancer.fr. 8. Department of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. rousseauf@ipc.unicancer.fr. 9. Department of Medical Oncology, Paoli-Calmettes Institute, BP 156, 13273, Marseille, France. raouljl@ipc.unicancer.fr.
Abstract
PURPOSE: To better know the presentation and outcome of pancreatic adenocarcinoma in patients above 75 years of age. METHOD: Retrospective analysis of consecutive patients with a pancreatic adenocarcinoma seen in the Comprehensive Cancer Center of Marseille between January 2002 and January 2012 was used. RESULTS: During these 10 years, 129 patients older than 75 years of age were seen, 61 females and 68 males, median age 78. At diagnosis, the tumor was metastatic in 45%. First line treatments were: surgical resection in 22 cases, radio-chemotherapy in 20 cases (1 operated on later), systemic chemotherapy in 59 cases, and best supportive care alone in 28 cases. Resection was possible in 19 cases and was R0 in 17; post-operative mortality was 0%, and half received adjuvant chemotherapy. Median overall survival was 43 months with a 2-year overall survival of 64%. For locally advanced tumor, 16 received best supportive care and 33 a specific treatment (20 cases of radio-chemotherapy). Median overall survival was 9.1 months and 2-year overall, survival was 6.1%. Among the 58 metastatic patients, 79% received systemic chemotherapy (most by gemcitabine); tolerance was correct in half. Median overall survival was 4.7 months, with a 2-year overall survival of 5.3%. CONCLUSIONS: Surgery of pancreatic adenocarcinoma is feasible and safe in elderly patients with good outcomes. In advanced and metastatic patients, the outcome is poor despite a correct tolerance of systemic chemotherapy. Randomized trials specially designed for this population are urgently needed.
PURPOSE: To better know the presentation and outcome of pancreatic adenocarcinoma in patients above 75 years of age. METHOD: Retrospective analysis of consecutive patients with a pancreatic adenocarcinoma seen in the Comprehensive Cancer Center of Marseille between January 2002 and January 2012 was used. RESULTS: During these 10 years, 129 patients older than 75 years of age were seen, 61 females and 68 males, median age 78. At diagnosis, the tumor was metastatic in 45%. First line treatments were: surgical resection in 22 cases, radio-chemotherapy in 20 cases (1 operated on later), systemic chemotherapy in 59 cases, and best supportive care alone in 28 cases. Resection was possible in 19 cases and was R0 in 17; post-operative mortality was 0%, and half received adjuvant chemotherapy. Median overall survival was 43 months with a 2-year overall survival of 64%. For locally advanced tumor, 16 received best supportive care and 33 a specific treatment (20 cases of radio-chemotherapy). Median overall survival was 9.1 months and 2-year overall, survival was 6.1%. Among the 58 metastatic patients, 79% received systemic chemotherapy (most by gemcitabine); tolerance was correct in half. Median overall survival was 4.7 months, with a 2-year overall survival of 5.3%. CONCLUSIONS: Surgery of pancreatic adenocarcinoma is feasible and safe in elderly patients with good outcomes. In advanced and metastatic patients, the outcome is poor despite a correct tolerance of systemic chemotherapy. Randomized trials specially designed for this population are urgently needed.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: O Turrini; F Paye; P Bachellier; A Sauvanet; A Sa Cunha; Y P Le Treut; M Adham; J Y Mabrut; L Chiche; J R Delpero Journal: Eur J Surg Oncol Date: 2012-09-19 Impact factor: 4.424
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Guy Lahat; Ronen Sever; Nir Lubezky; Ido Nachmany; Fabian Gerstenhaber; Menahem Ben-Haim; Richard Nakache; Josef Koriansky; Josef M Klausner Journal: World J Surg Oncol Date: 2011-01-27 Impact factor: 2.754